SAN DIEGO, November 16, 2017 /PRNewswire/ --
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules
that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune
cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the
NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged
in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule
therapies for autoimmune disorders
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the
checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should
suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid
arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman
and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other
biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV
injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of
administration, potential control of toxicity and intellectual property protection."
There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known
to be working on utilizing small molecules to activate immune checkpoints (https://www.biocentury.com/bc-innovations/strategy/2017-08-10/how-immuno-oncology-targets-are-spawning-new-therapies-).
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the
immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase
I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune
disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and
uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
619-702-1404 Phone
619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc.